欧州の多癌スクリーニング市場の分析・予測：2023～2032年

欧州の多癌スクリーニングの市場規模は、2023年の5億5,000万米ドルから、予測期間中は15.93%のCAGRで推移し、2032年には20億9,000万米ドルの規模に成長すると予測されています。

多癌スクリーニング市場の成長は、リキッドバイオプシー検査の利用の高まりとさまざまな癌種の有病率の上昇によって促進されると予測されています。

欧州の多癌スクリーニング市場：イントロダクション

欧州の多癌スクリーニング市場は、癌の早期発見に対する意識の高まりとスクリーニング技術の進歩により、大きな成長を遂げています。多癌スクリーニングは、さまざまな癌を早期段階で発見する包括的なアプローチを提供し、治療成績を改善し、死亡率を低下させます。また、政府の支援策や医療政策、癌研究やスクリーニングプログラムへの投資の増加も市場拡大の原動力となっています。さらに、欧州における癌の負担増と高齢化も、効果的なスクリーニング戦略の必要性を際立たせています。癌診断率の向上と住民の健康増進に重点を置くことで、欧州の多癌スクリーニング市場は継続的な成長と革新を遂げ、同地域における癌治療の展望を形成する見通しです。

当レポートでは、欧州の多癌スクリーニングの市場を調査し、市場概要、市場成長への各種影響因子の分析、特許およびR&Dの動向、償還シナリオ、市場規模の推移・予測、主要国別の詳細分析、主要企業の分析などをまとめています。

目次

エグゼクティブサマリー

第1章 市場

• 市場範囲
• 調査手法

第2章 市場概要

• 市場概要
• 多癌スクリーニングのワークフロー分析
• 市場のフットプリントと成長の可能性
• 将来性
• COVID-19による市場への影響

第3章 産業考察

• 特許分析
  • 特許出願動向
  • 特許分析（国別）
  • 特許分析（地域別）
• 償還シナリオ
• サプライチェーン分析
• 価格分析（テストタイプ別）

第4章 市場力学

• 概要
• 影響分析
• 市場促進要因
  • 癌の早期発見は生存率の向上とより良い治療につながる
  • リキッドバイオプシーの人気の高まりによるスクリーニングの容易化
  • 癌の早期発見による治療費の削減
• 市場の課題
  • 多癌スクリーニング検査に関する認識の欠如
  • 予防治療としての高コスト性
• 市場機会
  • 癌診断に革命をもたらす多癌スクリーニング検査の強力なパイプラインの準備
  • 新しいバイオマーカーの定期的な発見

第5章 多癌スクリーニング市場：地域別

• 概要
• 欧州
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • スペイン
  • その他

第6章 企業プロファイル

• バリューチェーン
• エコシステムで活発な企業
• F. Hoffmann-La Roche Ltd

List of Figures

• Figure 1: Europe Multicancer Screening Market, $Billion, 2022 and 2032
• Figure 2: Share of Multicancer Screening Market (by Region), 2022
• Figure 3: Multicancer Screening Market: Research Methodology
• Figure 4: Primary Research Methodology
• Figure 5: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 6: Top-Down Approach (Segment-Wise Analysis)
• Figure 7: Multicancer Screening Workflow, End User Perspective
• Figure 8: Multicancer Screening Workflow, Laboratory Technician Perspective
• Figure 9: Europe Multicancer Screening Market, $Billion, 2021-2032
• Figure 10: COVID-19 Impact
• Figure 11: Multicancer Screening Market, Patent Analysis (by Year), January 2020-December 2022
• Figure 12: Multicancer Screening Market, Patent Analysis (by Country), January 2020-December 2022
• Figure 13: Multicancer Screening Market, Patent Analysis (by Region), January 2020-December 2022
• Figure 14: Supply Chain Analysis of the Multicancer Screening Market
• Figure 15: Multicancer Screening Market Dynamics
• Figure 16: Prevalence vs. Age-Standardized Death Rate of Cancer Globally, 2010-2019 (%)
• Figure 17: Liquid Biopsy vs. Tissue Biopsy
• Figure 18: Liquid Biopsy Clinical Trials (by Cancer Types), Share (%), 2023
• Figure 19: Out-of-Pocket Costs for Complete Treatment by Cancer Type and Stage Among Insured Patient, ($)
• Figure 20: Lead-Time Bias in Cancer Screening
• Figure 21: Screened vs. Non-Screened Cancer Patients per 1,000,000 Incidence Rate (50-79 Years)
• Figure 22: Multicancer Early Detection Tests + Usual Care Screening Costs vs. only Usual Care Screening Costs
• Figure 23: Multicancer Screening Market Snapshot (by Region), $Billion, 2022
• Figure 24: Multicancer Screening Market (by Region), $Billion, 2021-2032
• Figure 25: Europe Multicancer Screening Market, $Billion, 2021-2032
• Figure 26: Europe Multicancer Screening Market (by Country), $Million, 2021-2032
• Figure 27: Germany Multicancer Screening Market, $Million, 2021-2032
• Figure 28: France Multicancer Screening Market, $Million, 2021-2032
• Figure 29: U.K. Multicancer Screening Market, $Million, 2021-2032
• Figure 30: Italy Multicancer Screening Market, $Million, 2021-2032
• Figure 31: Spain Multicancer Screening Market, $Million, 2021-2032
• Figure 32: Rest-of-Europe Multicancer Screening Market, $Million, 2021-2032
• Figure 33: Multicancer Screening Market, Total Number of Companies Profiled
• Figure 34: Multicancer Screening Market: Value Chain
• Figure 35: F. Hoffmann-La Roche Ltd: Product Portfolio
• Figure 36: F. Hoffmann-La Roche Ltd: Overall Financials, 2020-2022
• Figure 37: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2020-2022
• Figure 38: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2020-2022

List of Tables

• Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Multicancer Screening Market
• Table 2: Technological Trends in Multicancer Screening Market
• Table 3: Average Prices of Multicancer Screening Kits Calculation
• Table 4: Likert Scale
• Table 5: Impact Analysis of Market Drivers
• Table 6: Impact Analysis of Market Challenges
• Table 7: Five-Year Survival Rates for Different Cancers at Different Stages
• Table 8: Top Multicancer Screening Tests and Their Costs ($)
• Table 9: Multicancer Screening Market, Pipeline Tests
• Table 10: Cancers and Their Most Common Biomarker Tests

The Europe Multicancer Screening Market Expected to Reach $2.09 Billion by 2032

Introduction to Europe Multicancer Screening Market

The Europe multicancer screening market is projected to reach $2.09 billion by 2032 from $0.55 billion in 2023, growing at a CAGR of 15.93% during the forecast period 2023-2032. The multicancer screening market's growth is expected to be propelled by the heightened use of liquid biopsy testing and the escalating prevalence of various cancer types.

Market Introduction

The Europe Multicancer Screening Market is witnessing significant growth due to increasing awareness about early cancer detection and advances in screening technologies. Multicancer screening offers a comprehensive approach to detecting various cancers in their early stages, improving treatment outcomes and reducing mortality rates. Additionally, supportive government initiatives and healthcare policies, along with rising investments in cancer research and screening programs, are driving market expansion. Furthermore, the growing burden of cancer and aging population in Europe accentuates the need for effective screening strategies. With a focus on improving cancer diagnosis rates and enhancing population health, the Europe Multicancer Screening Market is poised for continued growth and innovation, shaping the landscape of cancer care in the region.

Market Segmentation:

Segmentation 1: by Country

• Germany
• France
• U.K.
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The key components in Europe multicancer screening are the kits and the related technologies for sample analysis. The advancements in new analysis methods like liquid biopsy are influencing the growth of this market. Additionally, the discovery of biomarkers and other genes for various diseases is helping panel manufacturers curate precise kits and assays for multicancer screening of various cancer types.

Competitive Strategy: The key players in the Europe multicancer screening market have been analyzed and profiled in the study, consisting of most product-based companies, as well as a few emerging companies. Moreover, a detailed competitive benchmarking of the players operating in the Europe multicancer screening market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1 Markets

• 1.1 Market Scope
  • 1.1.1 Key Questions Answered in the Report
• 1.2 Research Methodology
  • 1.2.1 Multicancer Screening Market: Research Methodology
  • 1.2.2 Data Sources
  • 1.2.3 Market Estimation Model
  • 1.2.4 Criteria for Company Profiling

2 Market Overview

• 2.1 Market Overview
• 2.2 Multicancer Screening Workflow Analysis
• 2.3 Market Footprint and Growth Potential
• 2.4 Future Potential
• 2.5 COVID-19 Impact on the Market

3 Industry Insights

• 3.1 Patent Analysis
  • 3.1.1 Patent Filing Trend
  • 3.1.2 Patent Analysis (by Country)
  • 3.1.3 Patent Analysis (by Region)
• 3.2 Reimbursement Scenario
• 3.3 Supply Chain Analysis
• 3.4 Pricing Analysis (by Test Type)

4 Market Dynamics

• 4.1 Overview
• 4.2 Impact Analysis
• 4.3 Market Drivers
  • 4.3.1 Early Detection of Cancer Leads to Higher Survival Chances and Better Treatment
  • 4.3.2 Increasing Popularity of Liquid Biopsy Leading to Easier Screening
  • 4.3.3 Reduced Treatment Cost Due to Earlier Cancer Detection
• 4.4 Market Challenges
  • 4.4.1 Lack of Awareness about the Multicancer Screening Tests
  • 4.4.2 Too Costly to be Used as Preventive Care
• 4.5 Market Opportunities
  • 4.5.1 Robust Pipeline of Multicancer Screening Tests Poised to Revolutionize Cancer Diagnosis
  • 4.5.2 New Biomarkers being Discovered Regularly

5 Multicancer Screening Regional Market, 2021-2032

• 5.1 Overview
• 5.2 Europe
  • 5.2.1 Germany
  • 5.2.2 France
  • 5.2.3 U.K.
  • 5.2.4 Italy
  • 5.2.5 Spain
  • 5.2.6 Rest-of-Europe

6 Company Profiles

• 6.1 Overview
• 6.2 Market Value Chain of Multicancer Screening Market
• 6.3 Multicancer Screening Ecosystem Active Players
• 6.4 F. Hoffmann-La Roche Ltd
  • 6.4.1 Company Overview
  • 6.4.2 Role of F. Hoffmann-La Roche Ltd in the Multicancer Screening Market
  • 6.4.3 Key Competitors of the Company
  • 6.4.4 Financials
  • 6.4.5 Corporate Strategies
  • 6.4.6 Business Strategies
  • 6.4.7 Analyst Perspective